Kiniksa Pharmaceuticals International (KNSA) Operating Income (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Operating Income of $29.3 million for Q1 2026, up 48.05% on a QoQ basis from $19.8 million in Q4 2025, and up 120.52% year-over-year from $13.3 million in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Operating Income (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Operating Income history runs 10 years deep, the most recent figure standing at $29.3 million for Q1 2026.
- Quarterly Operating Income rose 120.52% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.2 million (up 689.9% YoY) and the FY2025 annual result came in at $77.2 million, up 269.28% from the prior year.
- Operating Income was $29.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $19.8 million in the prior quarter.
- Across five years, Operating Income topped out at $46.4 million in Q3 2022 and bottomed at -$23.3 million in Q1 2022.
- A 5-year average of $2.7 million and a median of -$117000.0 in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income tumbled 23925.93% — and 2025, when it surged 17330.77%.
- Kiniksa Pharmaceuticals International's Operating Income stood at $6.0 million in 2022, then slumped by 98.66% to $81000.0 in 2023, then tumbled by 23925.93% to -$19.3 million in 2024, then soared by 202.43% to $19.8 million in 2025, then soared by 48.05% to $29.3 million in 2026.
- Business Quant data shows KNSA's Operating Income at $29.3 million in Q1 2026, $19.8 million in Q4 2025, and $24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.78 Bn | 4.31 Bn | 193.47 Mn | 29.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.27 Mn |
| Dec 31, 2025 | 19.77 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 20.16 Mn |
| Mar 31, 2025 | 13.27 Mn |
| Dec 31, 2024 | -19.30 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Jun 30, 2024 | -117,000.00 |
| Mar 31, 2024 | -16.54 Mn |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | -10.93 Mn |
| Jun 30, 2023 | -3.15 Mn |
| Mar 31, 2023 | -11.20 Mn |
| Dec 31, 2022 | 6.05 Mn |
| Sep 30, 2022 | 46.41 Mn |
| Jun 30, 2022 | -19.37 Mn |
| Mar 31, 2022 | -23.32 Mn |
| Dec 31, 2021 | -36.13 Mn |
| Sep 30, 2021 | -30.67 Mn |
| Jun 30, 2021 | -40.56 Mn |